en · de · es · fr · pt
selank-notes.peptides1126.com › Wiki › Proposed Mechanisms And Research Endpoints — 2026 Update

Proposed Mechanisms And Research Endpoints — 2026 Update

By Editorial Desk · published 2025-09-14 · last reviewed 2025-10-03 · Wiki

batch purity comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-10-03. Numbers and descriptions here follow the published literature rather than marketing material.

Proposed Mechanisms and Research Endpoints

Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.

Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.

Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.

Background and Peptide Identity

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Selank at a glance

PropertyValueNotes
Principal proposed targetGABA-A receptor complexHypothesis derived mainly from animal pharmacology
Common behavioral assayElevated plus mazeRodent test for anxiety-like behavior
Reported molecular markerHippocampal BDNF expressionMeasured by immunoassay or mRNA quantification
Typical dosing routeIntranasalChosen to reduce first-pass metabolism
Reported plasma half-lifeMinutesBased on limited peptide stability data

Selank Background and Peptide Chemistry

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.

Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.

Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.

Related pages on this site

Peptide Identity and Structure

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.

The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.

Stability, Handling, and Analytical Control

Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.

Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.

Selank Background And Chemical Identity

Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.

The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.

Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.

Supporting material

=== Surface-to-air missiles === Thunderbird (missile) – In use till 1977 for mobile high-altitude air defence. Bloodhound (missile) – Fixed air defence in UK from 1958 till 1991. Blowpipe (missile) – Man portable surface-to-air missile from 1975 till 1985 Rapier (missile) – Came into service at the start of 1970s and at the end replaced Bofors and thunderbird. Used until 2022. Javelin (surface-to-air missile) – Man portable surface-to-air missile replacing Blowpipe in use from 1984 to 1993.

For services to Health Care. Arthur Derek Hill. For services to Art. Jenny Hughes, , Chairman, Riverside Mental Health NHS Trust. For services to Health. Kenneth Wesley Jarrold, Director of Human and Corporate Resources, NHS Executive, Department of Health. George MacDonald Kennedy, Chairman, Smiths Industries Medical Systems. For services to the Health Care Industry and to Export. Cecil Gordon Knight, , Headteacher, Small Heath School, Birmingham. For services to Education. Simon Timothy Lee. For political service. Thomas Peter Ruffell Laslett. For services to the Cambridge Group for the History of Population and Social Structure. Robert Noyes Lawton. For services to Agriculture in Wessex. Martyn John Dudley Lewis, Chair, Drive for Youth and Youthnet UK. For services to Young People and to the Hospice Movement. Francis David Lindley Loy, lately Chairman, Provincial Stipendiary Magistrates' Association. John Lumsden, Chief Executive, Motherwell Bridge Group. For services to the Engineering Industry. Thomas George Mackey. For services to Urban Regeneration. Colin Barry Manchip, lately Director, Immigration Service (Enforcement), Home Office. Brenda Mary McLaughlin. For services to the community and to Health Care. Elizabeth Mary McLoughlin, Head of Civilian Management (Policy), Ministry of Defence. James David Frederick Miller, Chairman, Scottish Qualification Authority. For services to Education. Dominic Charles Bernard Morris, lately Deputy Head, Policy Unit, 10 Downing Street. Richard Brian Mouatt, lately Chief Dental Officer, Department of Health.

=== Radioactive carcinogens === In addition to chemical, nonradioactive carcinogens, chewing tobacco and tobacco smoke contain small amounts of lead-210 (210Pb) and polonium-210 (210Po), both of which are radioactive carcinogens. The presence of polonium-210 in mainstream cigarette smoke has been experimentally measured at levels of 0.0263–0.036 pCi (0.97–1.33 mBq), which is equivalent to about 0.1 pCi per milligram of smoke (4 mBq/mg); or about 0.81 pCi of lead-210 per gram of dry condensed smoke (30 Bq/kg). Research by NCAR radiochemist Ed Martell suggested that radioactive compounds in cigarette smoke are deposited in "hot spots" where bronchial tubes branch, that tar from cigarette smoke is resistant to dissolving in lung fluid and that radioactive compounds have a great deal of time to undergo radioactive decay before being cleared by natural processes. Indoors, these radioactive compounds can linger in passive smoke, and greater exposure would occur when these radioactive compounds are inhaled during normal breathing, which is deeper and longer than when inhaling cigarettes. Damage to the protective epithelial tissue from smoking only increases the prolonged retention of insoluble polonium-210 compounds produced from burning tobacco. Martell estimated that a localized carcinogenic radiation dose of 80–100 rads is delivered to the lung tissue of most smokers who die of lung cancer. Smoking an average of 1.5 packs per day may give a high localized dose to the bronchial epithelial a radiation dose up to 60–160 mSv/year.

Sources: en.wikipedia.org

Supporting material

=== Breast cancer === Hormone antagonists are used widely in anticancer treatments, such as the drug tamoxifen, an anti-estrogen that binds to estrogen receptors to slow the growth of some estrogen receptor-positive breast cancers. Aromatase inhibitors (AIs) are also prescribed as a breast cancer treatment, especially after mastectomies. AIs work by blocking the action of the aromatase enzyme, which converts androgens, like testosterone, into estrogen. Aromatase inhibitors can be used in conjunction with estrogen receptor inhibitors to treat estrogen receptor-positive breast cancers in women who have gone through menopause already.

== Description == The ESG may be performed with slight variations by different physicians. It most commonly is performed using the Apollo ESG Device (formally Overstitch device). This device fits over a therapeutic double-channel endoscope to create a sutured row of stomach tissue. The tissue helix is advanced from the endoscope, put up against stomach tissue, and turned 2-4 rotations to access the gastric muscle layer. The helix is then retracted towards the scope, bringing the full-thickness acquired stomach tissue with it. Using the handle-operated needle driver, a needle attached to the suture wire is passed through the full-thickness tissue to the anchor exchange. This creates a full-thickness plication of stomach tissue. The needle is then passed back from the anchor exchange to the needle driver, and the process is repeated, threading the suture wire through each bite of stomach tissue. When enough full-thickness bites have been taken for a suture row, a cinch is passed through the scope over the suture. Typically, sutures are placed starting at the border of the antrum and gastric body at the incisura, then placed proximally up to the border of the gastric body and fundus. Each row of sutures can be a straight line or one of the variety of suture patterns reported in the literature, such as the "M," "Z," and "U" pattern as well as other novel patterns; nonetheless, to date, no suture pattern has been proven to be superior for weight loss. Regardless of suture pattern, creation of the ESG focuses on tissue imbrication along the greater curvature of the stomach.

==== Background ==== It is surprising to note that In 1980, there was no single chiral stationary phase available in the market for performing chiral chromatography. However, In late 1980s the subject of enantioselective chromatography attracted growing interest, particularly under the drive of the institution of Okamoto in Japan, the teams of Pirkle, and Armstrong in the US, Schurig and König in Germany, Lindner in Austria, and Francotte in Switzerland . The Polysaccharides, amylose and cellulose, form the most abundant chiral polymers on earth. These naturally occurring polysaccharides form basis for an important class of chiral selectors.

Sources: en.wikipedia.org

Frequently asked questions

How is Selank administered in studies?

Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.

What endpoints do researchers measure?

Behavioral endpoints include time spent in open arms of the elevated plus maze and avoidance latencies. Biochemical endpoints include BDNF concentration, cytokine levels, and monoamine metabolite ratios in brain tissue.

What are the main evidence gaps?

Most published studies are small, originate from a limited number of laboratories, and lack independent replication. Dose-response relationships, measured brain exposure, and long-term outcomes are not well characterized.

What type of molecule is Selank?

Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.

Network